Aquestive Therapeutics Posts Q4 Revenue Growth Amidst Legal Expenses, Guidance for 2026

Aquestive Therapeutics Inc reported Q4 2025 total revenue of $13 million, up 10% YoY, and full-year 2025 revenue of $44.5 million, down from $57.6 million in 2024. Manufacturing and supply revenue increased, while R&D expenses and net loss rose due to higher selling, general, and administrative expenses and one-time legal expenses. The company provided 2026 revenue guidance of $46 million to $50 million and non-GAAP adjusted EBITDA loss guidance of $30 million to $35 million.